Abstract: FR-PO0331
Decision Impact Study of kidneyintelX.dkd on Provider Management and Patient Engagement in a Community Care Practice Environment
Session Information
- Diabetic Kidney Disease: Progression, Predictive Tools, Therapeutics, and Outcomes
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 702 Diabetic Kidney Disease: Clinical
Authors
- Busch, Robert S., Albany Med Health System, Albany, New York, United States
- Donovan, Michael J., Icahn School of Medicine at Mount Sinai, New York, New York, United States
Background
KidneyintelX is an FDA-approved test predicting risk of progressive decline in kidney function (PDKF) in patients with diabetic kidney disease (DKD) stages 1-3b and is recommended in the KDIGO 2024 guidelines. The test combines plasma biomarkers with clinical data to stratify patients as low, intermediate / moderate, or high risk for a sustained 40% decline in eGFR or kidney failur over five years. We now present interim results on a prospective decision impact study in a community setting in upstate New York to assess how primary care physicians (PCPs) and their patients respond to test results, including changes in medication (dose/class), consult services, and patient engagement.
Methods
Interim analysis on 290 of 744 patients managed by 14 PCP’s from 13 different practice locations in the Albany region enrolled from 11/2021 to current. All providers received an on-line educational session and a study brochure on the test’s clinical and analytical validation studies. Providers and patients completed customized post-test questionnaires, and responses were compiled for consensus.
Results
KidneyintelX classified 290 patients as 60% low, 34% intermediate and 6% high risk for PDKF. Median age 69 years, uACR 38 ug/g, eGFR 58 mL/min/1.73m2 and A1C 7%. Of 286 completed PCP surveys, 86% reported a treatment change for intermediate-moderate/high-risk patients, with the most common actions being blood pressure optimization (e.g. ACE/ARBs), SGLT2 inhibitor initiation, health education, specialist referral, and statin use. (Figure 1) Among patients, 87% reported improved understanding of kidney risk, and 98% found the test helpful for enhancing kidney and overall health.
Conclusion
In this community-based setting, KidneyIntelX provided actionable information that supported targeted management plans to help slow DKD progression.
Funding
- Commercial Support – Renalytix